Episodes
Friday Jan 19, 2024
Friday Jan 19, 2024
Over 75% of heart failure with preserved ejection fraction (HFpEF) patients have a comorbid diagnosis of obesity. Obesity is an independent risk factor for the development of HFpEF and contributes to disease progression. Obese patients with HFpEF have greater symptom burden, reduced functional capacity, and impaired quality of life when compared to those without obesity. We know that patients often struggle to adhere to lifestyle modifications long enough to see meaningful weight loss, but the benefits of GLP-1 agonists for patients with HFpEF who are obese are not yet clear.
Guest Authors: Alicia M. Nordberg-Payne, PharmD; Rebecca Munger, PharmD, BCACP; Jason Zupec, PharmD, BCACP
Music by Good Talk
Friday Aug 11, 2023
Making the GRADE: Durability of Glycemic Response in Type 2 Diabetes
Friday Aug 11, 2023
Friday Aug 11, 2023
Type 2 diabetes (type 2 DM) is a progressive disease caused by a variety of pathophysiologic defects. However, even with substantial advances in treatment, glycemic control remains elusive, and most patients require combination therapy. The Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) study sought to investigate the glucose-lowering efficacy of several diabetes medications in combination with metformin.
Guest Authors: Katelyn Currier, PharmD and Jennifer Trujillo, PharmD, BCPS, CDCES, BC-ADM
Music by Good Talk
Friday May 12, 2023
GLP-1 Receptor Agonists and SGLT2 Inhibitors: Don’t Sugarcoat the Costs!
Friday May 12, 2023
Friday May 12, 2023
The cost of diabetes in the United States has nearly doubled over the past decade in part due to rising prices and the cost of newer medications used to manage the disease. With new, improved, but costly alternatives available, it’s going to be challenging for ambulatory care practitioners to evaluate if the potential benefits of using these newer medication classes as first-line therapy (instead of metformin) outweigh their big price tag.
Guest Authors: Amanda Smith, PharmD and Nicole Slater, PharmD, BCACP
Music by Good Talk
Friday Dec 03, 2021
Will a Dual GIP/GLP-1 Receptor Agonist SURPASS the Crowd?
Friday Dec 03, 2021
Friday Dec 03, 2021
There are now over 30 unique therapeutic entities (and countless different products!) to treat hyperglycemia in patients with type 2 diabetes mellitus (T2DM). While the glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control, renal, and cardiovascular outcomes and induce significant weight loss, drugs that target more than one incretin hormone may have even greater therapeutic benefits.
Guest Authors: Nadila Faridi, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP
Special Guest: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES
Music by Good Talk
Friday Jul 16, 2021
STEP-ping Up the Game for Weight Management
Friday Jul 16, 2021
Friday Jul 16, 2021
More than two-thirds of adults in the United States are overweight or obese — thus, obesity is, by far, the most common preventable health-related problem seen in practice today. Obesity is associated with several comorbidities, and weight reduction leads to positive outcomes in many diseases. Studies have shown that a weight loss of 10% improves cardiovascular risk and outcomes. Unfortunately, current pharmacological options for weight loss do not consistently achieve a 10% weight loss. Can semaglutide deliver?
Guest Panelists: Teney Mathew, PharmD, Jason Zupec, PharmD, BCACP, and Amy Heck Sheehan, PharmD, BCPS
Music by Good Talk
Thursday Oct 24, 2019
Will Oral Semaglutide PIONEER the Way to Lower Cardiovascular Risk?
Thursday Oct 24, 2019
Thursday Oct 24, 2019
Until recently, glucagon-like-peptide-1 (GLP-1) receptor agonists were only available as injectable products. Some clinicians and patients are reluctant to use injectable agents because they require additional patient education and can be intimidating. If a GLP-1 receptor agonist were available in an oral dose form, it would be welcomed treatment option. But would the cardiovascular safety and benefits of oral GLP-1 receptor agonists be better, similar, or worse than their injectable siblings?
Guest Authors: Sally Earl, PharmD, BCPS and Megan Supple, PharmD, BCACP
Music by Good Talk
Friday Jan 13, 2017
Is there a Role for Fixed-Ratio Injectable Combinations in Type 2 Diabetes?
Friday Jan 13, 2017
Friday Jan 13, 2017
Pharmacotherapy for diabetes management has expanded in recent years with several new drug classes. Current guidelines recommend several options for patients who have not reached their goal A1c on metformin monotherapy including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or basal insulin. However, if basal insulin is chosen as the first add-on treatment with metformin, the post-prandial blood glucose (PPG) often will remain elevated. A combination product that includes both a basal insulin plus a GLP-1 RA has the potential to addresses both fasting blood glucose and PPG … and perhaps has some other advantages over using either product alone.
Theme Music by Good Talk
Friday Sep 02, 2016
Liraglutide: the new LEADER for second line therapy in diabetes management?
Friday Sep 02, 2016
Friday Sep 02, 2016
According to the current (2016) ADA guidelines, no agent is “the preferred” second line therapy after metformin monotherapy — instead the benefits, risks, cost, and convenience of each option should be considered and treatment should be individualized. The liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER) trial, which assessed the long-term cardiovascular effects of liraglutide, a GLP-1 receptor agonist, comes at an interesting time shortly after the publication of the empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME) trial. Both studies found a cardiovascular benefit. How, then, will the results of these trials affect the algorithm for type 2 diabetes management and more importantly, clinical practice?
Friday Apr 22, 2016
Lixisenatide and Cardiovascular Outcomes: The Burden of Proof
Friday Apr 22, 2016
Friday Apr 22, 2016
After cardiovascular (CV) safety concerns emerged with rosiglitazone use, the Food and Drug Administration (FDA) now requires outcome studies to be performed for all new diabetes medications. The first CV safety study (ELIXA) for a drug in the glucagon-like peptide 1-receptor agonist (GLP-1 RA) class – lixisenatide - was published in December 2015. Lixisenatide is a once-daily injectable GLP-1 RA approved for use in Europe and awaits FDA approval in the United States.